Stem Cell Therapeutics Corp has been advised by the Data Safety Monitoring Board (DSMB) that a regularly scheduled safety analysis has been completed and the DSMB has recommended the phase-IIb stroke trial to continue as per the protocol.

The DSMB is a group of independent clinical experts that review the ongoing conduct of a clinical trial to ensure continuing patient safety. The mandate of SCT's DSMB is to provide objective, independent monitoring of patient safety during the phase-IIb stroke trial. This review was the first of three formal meetings scheduled that will occur over the duration of the phase-IIb stroke trial.

Dr Alan Moore, president and CEO said, "We are very pleased to receive a positive safety review of the phase-IIb stroke trial. Review results and enrolment updates will be announced after each DSMB meeting as progress continues for the phase-IIb trial. We are also happy to report that 32 patients are currently enrolled in our phase-IIb stroke study. At this time, we estimate that Phase IIb patient enrollment will be complete by the end of Q1 2010 or early in Q2 2010. This will be followed by a 90-day period for completion of patient assessments so we expect top-line data to be available by the end of Q2 2010 or early in Q3 2010."

Stem Cell Therapeutics Corp is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.